Home > Cluster Organisations > Cluster for Individualized Immune Intervention (Ci3)

Cluster for Individualized Immune Intervention (Ci3)

Primary tabs

Printer-friendly versionPrinter-friendly version
General Information
The date when the cluster organisation was established: 
Saturday, 24 July, 2010
Number of staff in the management team of the cluster organisation : 
1-5
Regions: 
Rheinhessen-Pfalz
Other Label: 
Winner Spitzencluster Wettbewerb
Membership to other networks/partnerships: 
Cluster Management Team: 
NameSurnamePositionTelephoneEmailGender
Tobias
Neumann
Project Manager
+4961312169771
neumann@ci-3.de
Male
Andrée
Rothermel
Cluster Manager
+4961312161420
rothermel@ci-3.de
Male
Languages spoken: 
English
German
Sectoral and Industrial Focus
Sectoral Industries: 
Biopharmaceuticals
Technology fields: 
Bioinformatics
Medical Research
S3 EU priority areas: 
e-Health (e.g. healthy ageing)
Human health activities (medical services)
Emerging industries: 
Biopharmaceuticals
Areas of specialisation of the cluster not covered above: 
Pharmaceutical Products / Drugs; Human vaccines; Clinical Research, Trials; Cytology, Cancerology, Oncology; Diagnostics, Life Sciences
Composition of the cluster
Total number of members: 
100
Number of SME members: 
48
Number of larger company members: 
21
Number of research organisations/universities/technology centres: 
23
Entrepreneurship and scale-up support facilities in the cluster's ecosystem (see "Organisation type"): 
Name and link of major players: 
NameWebsiteType
BioNTech
Larger Company
TRON
Research Organisation
Merck
Larger Company
Cluster Strategy
Mission/Objectives: 

The Cluster for Individualized Immune Intervention (Ci3) promotes the development of innovative immunotherapies and diagnostics for serious diseases with an unmet medical need. Its strong network of pharmaceutical and biotechnology companies, universities, and other research institutions is located in the Rhine-Main area, a region with one of Europe’s longest and most successful histories in pharmaceutical innovations. Through the cluster's combined expertise and international collaborations, Ci3 aims to advance personalized medicine by breaking down innovation barriers and enabling disruptive technologies.

 

Do you have a formalised strategy?: 
No
Do you have a specific strategy focus that addresses internationalisation ?: 
No
Services
Support services provided: 
Access to the European Internal market
Access to public support (regional/national programmes, innovation vouchers, etc.)
Facilitation of collaboration between members
Facilitation of cross-sectorial cooperation
Promotion of activities (marketing/ visibility)
Cooperation Activities
International Cooperation
The main countries targeted by the cluster organisation: 
None
Trans-national Cooperation
The main countries targeted by the cluster organisation: 
Austria
Greece
Norway
Portugal
Spain
Our cluster organisation undertook the following trans-national activities to support our members: 
Promotional Activities
Which clusters do you collaborate with?: 
Oslo Cancer Cluster S.A (EU)
Oncotyrol, Center for Personalized Cancer Medicine GmbH (EU)
IT-Cluster - Business Upper Austria, OÖ Wirtschaftsagentur GmbH (EU)
BioRN - Life Science Cluster Rhine-Neckar (EU)
Support Programmes
Participation in Funded Support Programmes: 
European ProgrammesProject NameLinkName & Description (Regional/National)Link (Regional/National)
H2020

Project 1. Permides: It is the aim of PERMIDES to strengthen the competitiveness and foster the innovation potential of personalized medicine as an emerging industry in Europe by providing key solutions for the reconfiguration of the biopharmaceutical value chain towards a Health Economy 4.0 with a special focus on oncology (i.e. cancer treatment). Current value chain challenges lie in e.g. data gathering and exchange, big data and machine learning, or new software-based marketing methods. Via a cross-clustering approach, leading biopharma and IT clusters from three countries (Austria, Germany, and Norway) will create novel cross-sectoral collaborations between SMEs to address innovation barriers in the biopharma sector via cutting-edge IT solutions. As a cross-cutting industry, the ICT and software sector is an enabler of innovation in many industries and therefore provides a broad knowledge base of processes and best practice solutions in diverse industrial contexts and business environments.

Project 2. Digi-B-Cube (Digital Enterprise Innovations for Bioimaging, Biosensing and Biobanking Industries) The DIGI-B-CUBE project aims to unlock the cross-sectoral collaborative potential of SMEs by combining artificial intelligence (AI) and cognitive computing digital technologies (CCDT) with the bioimaging-biosensing-biobanking (B-CUBE) industries to deliver market sensitive disruptive technologies, and by generating innovative solutions that enhance patient-centred diagnostic work-flows, delivered through the improved algorithms for the efficiency and accuracy of medical diagnostics. DIGI-B-CUBE will study the characteristics in market dynamics & specificities for innovations created by merging AI, CCDT & B-CUBE industries. By providing a framework for a more structured cross-sectoral and cross-border collaboration that manages all of the complex workflows within the process, DIGI-B- CUBE instantiates the mechanisms to ensure long-term sustainability of the action through collaborations of the participating clusters with hospitals, academia, industry, investors, business angels, managing authorities of the national innovation agencies, and the European Commission support measures (such as EIT, ESIF). The main objective of this project is to provide key digital solutions for the reconfiguration of the medical diagnostics value chain towards a Health Economy 4.0 with a special focus on the biobanking, bioimaging and biosensing industries. Activities financed by the ESIF in the participating regions as part of the Smart Specialisation Strategies will be bundled in cooperation with the responsible managing authorities in addition to the innovation voucher scheme for SMEs. By integrating innovations in IT into bioimaging, biosensing and biobanking industries, this project will accelerate the goal of personalised medicine that can eventually offer patients a fast and efficient diagnosis-treatment-healthcare system.

HAEP (Health Axis Europe Partnering): The project aims to bundle the innovative strengths of science and industry and will provide a new tool for facilitated international knowledge exchange between academia and small and medium-sized enterprises on the one side and global healthcare companies on the other. It effectively matches innovation seekers with innovators from a broad international network.

Promotion
Success Story / Achievements: 
  • Setting up of an innovative network of partners working in the field of immunoncology, infectious and autoimmune diseases, in particular individualized cancer immunotherapies. Successful implementation of new therapeutic concepts into clinic.
  • Development of innovative bioinformatics tools for individualized and personalized medical approaches. 
  • Connecting SME and research institution with large pharmaceutical companies, translating innovative technologies from basic research into the clinic.
Why should partners choose you for cooperation?: 

Ci3 offers a strong multidisciplinary and translational network in the life sciences sector with experince in:

  • cancer immunotherapies
  • infectious diseases
  • bioinformatics  
  • digitization
  • promotion of translational science by connecting research institutions, SMEs, and large scale enterprises